ANTI-BAGHOLDER
11 months ago
Interesting 8k
On November 21, 2023, (the βExecution Dateβ) Bellicum Pharmaceuticals, Inc., a Delaware corporation (the βCompanyβ), and The University of Texas M. D. Anderson Cancer Center, an institution of higher education and an agency of the State of Texas (βMDACCβ), entered into an Asset Purchase Agreement (the βAsset Purchase Agreementβ) pursuant to which MDACC will acquire substantially all of the Companyβs assets, including all rights to each program of research and development related to (i) CaspaCIDe (inducible caspase-9), the Rimiducid-inducible safety switch designed to abrogate high-grade adverse events associated with genetically-modified cell therapies, (ii) inducible MyD88/CD40 (iMC), the Rimiducid-inducible activation switch designed to enhance effector cell proliferation and persistence and to resist exhaustion and inhibitory signals, (iii) dual-switch GoCAR-T, incorporating both iMC and a modified rapalog-inducible caspase-9 safety switch, and (iv) Rimiducid (the βAsset Saleβ). Pursuant to the Asset Purchase Agreement, MDACC will pay to the Company an amount equal to $8.1 million in cash and will assume certain related